RVX-297 reduces histopathology in mouse models of arthritis
Histopathology was assessed and scored based on polyarticular inflammation, cartilage destruction, pannus formation, and bone resorption (outlined at www.bolderbiopath.com). Doses were delivered twice per day in 10 mice/group. Results are presented as percent reduction compared with vehicle-treated mCIA or mCAIA controls, and data are shown as the mean ± S.D. Statistical significance compared with the vehicle-treated controls was determined using a Student’s t test.
| Percent reduction in histopathology score | |||||
|---|---|---|---|---|---|
| mCIA | mCAIA | ||||
| RVX-297 75 mg/kg | RVX-297 150 mg/kg | Dexamethasone 0.2 mg/kg | RVX-297 150 mg/kg | Dexamethasone 0.5 mg/kg | |
| All paw | 65 ± 19*** | 79 ± 20*** | 92 ± 12*** | 49 ± 50 | 94 ± 19*** |
| Knee | 70 ± 32*** | 92 ± 13*** | 87 ± 21*** | 73 ± 13* | 100 ± 0** |
| Six-joint | 66 ± 21*** | 83 ± 18*** | 91 ± 13*** | N.D. | N.D. |
| Three-joint | N.D. | N.D. | N.D. | 56 ± 33* | 96 ± 13*** |
N.D., not determined.
↵* P < 0.05; **P < 0.01; ***P < 0.001.